Needham & Company Downgrades Verrica Pharmaceuticals (VRCA) to Hold, Removes Price Target on "Uncertain Delay", Reiterates that "Ycanth Has a Bright Commercial Future"
Tweet Send to a Friend
Needham & Company analyst Serge Belanger downgraded Verrica Pharmaceuticals (NASDAQ: VRCA) from Buy to Hold and removed a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
